A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy
Trial details
- Registry ID
- NCT06643260
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and EfficacyNCT06643260 | Can-Fite BioPharma | Phase 3 | Not yet recruiting | 2027-12Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |